Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. The forefront of ovarian cancer therapy: update on PARP inhibitors

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. L-Lysine increased the cytotoxicity effect of doxorubicin in MDA-MB-231 and MDA-MB-468 breast cancer cell lines

    Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskning

  3. TSGA10 and H2AX competition over binding HIF-1 in breast cancer

    Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

  1. The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Diagnostic challenges in clinical, radiological and histopathological tests regarding papillomatous lesions of the breast

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Is DBCG abreast of new developments?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • G Viale
  • M M Regan
  • P Dell'Orto
  • M G Mastropasqua
  • E Maiorano
  • B B Rasmussen
  • G MacGrogan
  • J F Forbes
  • R J Paridaens
  • M Colleoni
  • I Láng
  • B Thürlimann
  • H Mouridsen
  • L Mauriac
  • R D Gelber
  • K N Price
  • A Goldhirsch
  • B A Gusterson
  • A S Coates
  • BIG 1-98 Collaborative and International Breast Cancer Study Groups
Vis graf over relationer
On average, aromatase inhibitors are better than tamoxifen when used as initial or sequential therapy for postmenopausal women with endocrine-responsive early breast cancer. Because there may be contraindications to their use based on side-effects or cost, we investigated subgroups in which aromatase inhibitors may be more or less important.
OriginalsprogEngelsk
TidsskriftAnnals of Oncology
Vol/bind22
Udgave nummer10
Sider (fra-til)2201-7
Antal sider7
ISSN0923-7534
DOI
StatusUdgivet - 2011

ID: 34753685